BRIEF published on 10/06/2026 at 22:10, 1 month 14 days ago Inventiva reveals progress at the AASLD The Liver Meeting 2026 Inventiva Lanifibranor MASH Treatment AASLD 2026 PPAR Activation
BRIEF published on 10/06/2026 at 22:10, 1 month 14 days ago Inventiva to Present Abstracts at 2026 Liver Meeting Inventiva MASH Lanifibranor PPAR Liver Meeting® 2026
PRESS RELEASE published on 10/06/2026 at 22:05, 1 month 14 days ago Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 Inventiva to present scientific abstracts on lanifibranor at AASLD The Liver Meeting® 2026, focusing on PPAR isoforms and epigenetic changes in MASH pathogenesis Inventiva MASH Lanifibranor AASLD PPAR Isoforms
BRIEF published on 09/08/2026 at 22:05, 2 months 12 days ago Inventiva to Showcase Lanifibranor Data at Paris MASH 2026 Clinical Data Inventiva MASH Lanifibranor PPAR Agonist
BRIEF published on 09/08/2026 at 22:05, 2 months 12 days ago Inventiva presents its advancements at the Paris MASH 2026 Congress Inventiva MASH Lanifibranor Clinical Phase PPAR
PRESS RELEASE published on 09/08/2026 at 22:00, 2 months 12 days ago Inventiva to Present Multiple Abstracts at Paris MASH 2026 Inventiva to present Phase 1 and Phase 2 clinical data on lanifibranor at Paris MASH 2026, showing improvements in metabolic and cardiovascular factors in MASH patients. Lanifibranor's pan-PPAR pharmacology highlighted Clinical Data Inventiva Lanifibranor Metabolic Dysfunction Paris MASH 2026
BRIEF published on 09/02/2026 at 22:10, 2 months 18 days ago Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study Clinical Study Phase 3 Inventiva MASH Lanifibranor
BRIEF published on 09/02/2026 at 22:10, 2 months 18 days ago Inventiva Completes Key Milestone in MASH Clinical Trial Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
PRESS RELEASE published on 09/02/2026 at 22:05, 2 months 18 days ago Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Inventiva completes last patient visit in Phase 3 trial for lanifibranor in MASH treatment, with topline results expected in Q4 2026. Financial results update scheduled for H1 2026 Phase 3 Trial Inventiva Lanifibranor MASH Treatment Financial Results Update
BRIEF published on 08/31/2026 at 22:10, 2 months 20 days ago Chris Benecchi appointed COO by Inventiva Biopharmaceutical Inventiva MASH Lanifibranor Chris Benecchi
Published on 11/20/2026 at 15:00, 17 hours 5 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 17 hours 15 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 18 hours 5 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 18 hours 35 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 18 hours 35 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 8 hours 20 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 10 hours 29 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 12 hours 39 minutes ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 13 hours 2 minutes ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 13 hours 31 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 14 hours 30 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 13 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 1 day 23 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing